Susceptibility of important Gram-negative pathogens to tigecycline and other antibiotics in Latin America between 2004 and 2010

Annals of Clinical Microbiology and Antimicrobials

Volumn 11, Issue , 2012, Pages

  Fernández Canigia, Liliana ^a   Dowzicky, Michael J ^b  

^a HOSPITAL ALEMÁN   (Argentina)

^b PFIZER INC   (United States)

Author keywords

Carbapenems; Latin America; Resistance; Susceptibility; Tigecycline

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; BROTH DILUTION; ENTEROBACTER; ESCHERICHIA COLI; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; NONHUMAN; QUALITY CONTROL; SERRATIA MARCESCENS;

ACINETOBACTER BAUMANNII; AMIKACIN; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTER; ESCHERICHIA COLI; IMIPENEM; KLEBSIELLA OXYTOCA; KLEBSIELLA PNEUMONIAE; LATIN AMERICA; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SERRATIA MARCESCENS; THIENAMYCINS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84867660290     PISSN: None     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-11-29     Document Type: Article

References (31)

1. Moet GJ, Jones RN, Biedenbach DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Diagn Microbiol Infect Dis 2007, 57:7-13. 10.1016/j.diagmicrobio.2006.05.009, 17059876.
2. Villegas MV, Kattan JN, Quinteros MG, Casellas JM. Prevalence of extended-spectrum β-lactamases in South America. Clin Microbiol Infect 2008, 14(Suppl 1):154-158.
3. Villegas MV, Blanco MG, Sifuentes-Osornio J, Rossi F. Increasing prevalence of extended-spectrum-β-lactamase among Gram-negative bacilli in Latin America - 2008 update from the Study for Monitoring Antimicrobial Resistance Trends (SMART). Braz J Infect Dis 2011, 15:34-39.
4. Dhillon RHP, Clark J. ESBLs: a clear and present danger?. Crit Care Res Pract 2012, 2012:625170. Epub 2011 Jun 6, 3135063, 21766013.
5. Gomez SA, Pasteran FG, Faccone D, Tijet N, Rapoport M, Lucero C, Lastovetska O, Albornoz E, Galas M, Melano RG, Corso A, Petroni A, KPC Group Clonal dissemination of Klebsiella pneumoniae ST258 harbouring KPC-2 in Argentina. Clin Microbiol Infect 2011, 17:1520-1524. 10.1111/j.1469-0691.2011.03600.x, 21851480, KPC Group.
6. Neonakis IK, Spandidos DA, Petinaki E. Confronting multidrug-resistant Acinetobacter baumannii: a review. Int J Antimicrob Agents 2011, 37:102-109. 10.1016/j.ijantimicag.2010.10.014, 21130607.
7. Rossi F, García P, Ronzon B, Curcio D, Dowzicky MJ. Rates of antimicrobial resistance in Latin America (2004-2007) and in vitro activity of the glycylcycline tigecycline and of other antibiotics. Braz J Infect Dis 2008, 12:405-415.
8. Clinical and Laboratory Standards Institute Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, Approved standard 2009, PA: Document M7-A8. Clinical and Laboratory Standards Institute Wayne, 8, ISBN ISBN 1-56238-689-1, Clinical and Laboratory Standards Institute.
9. Clinical and Laboratory Standards Institute Performance standard for antimicrobial susceptibility testing: 20th information supplement. Document M100-S20 2010, Wayne, PA: Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute.
10. Clinical and Laboratory Standards Institute Performance standard for antimicrobial susceptibility testing: 20th informational supplement (June 2010 update) 2010, Wayne, PA: Document M100-S20U, Clinical and Laboratory Standards Institute, Clinical and Laboratory Standards Institute.
11. Tygacil® Product Insert http://www.pfizerpro.com/hcp/tygacil.
12. Farrell DJ, Turnidge JD, Bell J, Sader HS, Jones RN. The in vitro evaluation of tigecycline tested against pathogens isolates in eight countries in the Asia-Western Pacific region (2008). J Infect 2010, 60:440-451. 10.1016/j.jinf.2010.03.024, 20361999.
13. Hawser SP, Bouchillon SK, Hoban DJ, Badal RE, Hsueh PR, Paterson DL. Emergence of high levels of extended-spectrum-β-lactamase-producing gram-negative bacilli in the Asia-Pacific region: data from the Study for Monitoring Antimicrobial Resistance Trends (SMART) program, 2007. Antimicrob Agents Chemother 2009, 53:3280-3284. 10.1128/AAC.00426-09, 2715591, 19506060.
14. Mosqueda-Gómez JL, Montaño-Loza A, Rolón AL, Cervantes C, Bobadilla-del-Valle JM, Silva-Sánchez J, Garza-Ramos U, Villasís-Keever A, Galindo-Fraga A, Palacios GM, Ponce-de-León A, Sifuentes-Osornio J. Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum β-lactamase-producing Klebsiella pneumoniae A case-control study. Int J Infect Dis 2008, 12:653-659. 10.1016/j.ijid.2008.03.008, 18511321.
15. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686. 10.1128/CMR.18.4.657-686.2005, 1265908, 16223952.
16. Martinez-Martinez L, Pascual A, Conejo Mdel C, Garcia I, Joyanes P, Domenech-Sanchez A, Benedi VJ. Energy-dependent accumulation of norfloxacin and porin expression in clinical isolates of Klebsiella pneumoniae and relationship to extended-spectrum beta-lactamase production. Antimicrob Agents Chemother 2002, 46:3926-3932. 10.1128/AAC.46.12.3926-3932.2002, 132737, 12435697.
17. Patterson JE, Hardin TC, Kelly CA, Gracia RC, Jorgensen JH. Association of antibiotic utilization measures and control of multiple-drug resistance in Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2000, 21:455-458. 10.1086/501787, 10926395.
18. Wirtz VJ, Dreser A, Gonzales R. Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Rev Panam Salud Publica 2010, 27:219-225.
19. Fernández Canigia L, Kaufman S, Lanata L, Vay C, Giovanakis M, Bantar C, Argentinean Tigecycline Surveillance Group Multicenter study to assess the in vitro activity of tigecycline by disk diffusion test against clinical isolates from Argentina. Chemotherapy 2009, 55:20-27. 10.1159/000167788, 18974645, Argentinean Tigecycline Surveillance Group.
20. Bantar C, Curcio D, Fernández Canigia L, García P, Guzmán Blanco M, Leal AL, Latin American Tigecycline Surveillance Group Comparative in vitro activity of tigecycline against bacteria recovered from clinical specimens in Latin America. J Chemother 2009, 21:144-152. Latin American Tigecycline Surveillance Group.
21. Melano R, Corso A, Petroni A, Centron D, Orman B, Pereyra A, Moreno N, Galas M. Multiple antibiotic-resistance mechanisms including a novel combination of extended-spectrum β-lactamases in a Klebsiella pneumoniae clinical strain isolated in Argentina. J Antimicrob Chemother 2003, 52:36-42. 10.1093/jac/dkg281, 12775675.
22. Martínez-Martínez L, Pascual A, Hernández-Allés S, Alvarez-Diaz D, Suárez AI, Tran J, Benedí VJ, Jacoby GA. Roles of β-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother 1999, 43:1669-1673. 89341, 10390220.
23. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, Quale J. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005, 165:1430-1435. 10.1001/archinte.165.12.1430, 15983294.
24. Radice M, Power P, Gutkind G, Fernández K, Vay C, Famiglietti A, Ricover N, Ayala JA. First class A carbapenemase isolates from Enterobacteriaceae in Argentina. Antimicrob Agents Chemother 2004, 48:1068-1069. 10.1128/AAC.48.3.1068-1069.2004, 353161, 14982814.
25. Pasteran FG, Otaegui L, Guerriero L, Radice G, Maggiora R, Rapoport M, Faccone D, Di Martino A, Galas M. Klebsiella pneumoniae carbapenemase-2, Buenos Aires, Argentina. Emerg Infect Dis 2008, 14:1178-1180. 10.3201/eid1407.070826, 2600346, 18598660.
26. Villegas MV, Lolans K, Correa A, Suarez CJ, Lopez JA, Vallejo M, Quinn JP, The Colombian Nosocomial Resistance Study Group First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 2006, 50:2880-2882. 10.1128/AAC.00186-06, 1538657, 16870793, The Colombian Nosocomial Resistance Study Group.
27. Gales AC, Jones RN, Sader HS. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY antimicrobial surveillance program (2006-2009). J Antimicrob Chemother 2011, 66:2070-2074. 10.1093/jac/dkr239, 21715434.
28. Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of Gram-negative and Gram-positive organisms: tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis 2009, 65:288-299. 10.1016/j.diagmicrobio.2009.07.010, 19733459.
29. Gales AC, Jones RN, Sader HS. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 2006, 12:315-321. 10.1111/j.1469-0691.2005.01351.x, 16524407.
30. Tognim MC, Andrade SS, Silbert S, Gales AC, Jones RN, Sader HS. Resistance trends of Acinetobacter spp. in Latin America and characterization of international dissemination of multi-drug resistant strains: five-year report of the SENTRY Antimicrobial Surveillance Program. Int J Infect Dis 2004, 8:284-291. 10.1016/j.ijid.2003.11.009, 15325597.
31. Bradford PA, Weaver-Sands DT, Petersen PJ. In vitro activity of tigecycline against isolates from patients enrolled in Phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 2005, 41:S315-S332. 10.1086/431673, 16080070.